By: Jerome Brookshire

For nearly a decade, Bayer has been ensnared in one of the most sprawling and consequential product-liability sagas in modern corporate history. On Tuesday, the German pharmaceutical and biotechnology conglomerate announced what it hopes will be a decisive turn in that long-running battle: a proposed $7.25 billion settlement designed to resolve tens of thousands of claims that its herbicide Roundup caused non-Hodgkin’s lymphoma.

The agreement, submitted for judicial review to a Missouri circuit court in St. Louis, represents the latest and perhaps most ambitious attempt by Bayer to corral a litigation crisis that has shadowed the company since it acquired Monsanto in 2016. As The New York Times reported on Tuesday, the Roundup controversy has become a defining test of corporate accountability, regulatory authority, and the capacity of the legal system to mediate scientific uncertainty.

The contours of the proposed settlement underscore both the magnitude of Bayer’s predicament and the fragility of any effort to draw a line under the controversy. If approved, the deal would establish a fund to compensate plaintiffs over a period of 17 to 21 years, covering not only existing lawsuits but also a broad category of future claims. It is a structure designed to provide Bayer with what executives describe as predictability in the face of a torrent of litigation that has, at times, seemed inexhaustible.

The New York Times has chronicled how earlier efforts to impose order on the legal chaos faltered, most notably in 2020, when a $10 billion settlement unraveled after a federal judge objected to provisions governing future claims. That judicial rebuke cast a long shadow over subsequent negotiations, reinforcing the lesson that any attempt to resolve the Roundup litigation must navigate not only financial realities but also the courts’ vigilance over procedural fairness.

For Bayer’s leadership, the new agreement is being framed as a milestone in a grueling campaign to contain legal exposure that has already cost the company dearly. Since acquiring Monsanto, Bayer has earmarked roughly $10 billion to settle Roundup-related lawsuits, a figure that would climb to nearly $14 billion if the latest agreement is approved. The New York Times report noted the paradox at the heart of Bayer’s predicament: the Monsanto acquisition, once touted as a strategic masterstroke that would vault the company to the forefront of agricultural biotechnology, has instead become a case study in the perils of corporate consolidation, saddling Bayer with liabilities that continue to reverberate across its balance sheet.

Bill Anderson, Bayer’s chief executive, sought to strike a note of cautious optimism in announcing the settlement. Calling the agreement an “important milestone,” he emphasized the company’s determination to bring stability to a legal environment that has been anything but stable. The market’s initial response appeared to validate that narrative; Bayer’s shares surged more than 7 percent following the announcement, reflecting investor relief at the prospect of reduced litigation uncertainty. Yet, such market reactions can be fleeting, particularly when the underlying legal and scientific disputes remain unresolved.

At the heart of the Roundup controversy lies a collision between regulatory determinations and jury verdicts. Bayer maintains that the Environmental Protection Agency has consistently found glyphosate, the active ingredient in Roundup, to be safe when used as directed. On that basis, the company argues that federal labeling standards should preempt state-law claims alleging that Monsanto failed to warn users about cancer risks.

Plaintiffs’ attorneys, however, have persuaded juries in multiple state-court trials that Roundup exposure contributed to plaintiffs’ non-Hodgkin’s lymphoma, securing verdicts that in some cases reached hundreds of millions of dollars before being pared back on appeal. The New York Times has chronicled these courtroom dramas in granular detail, highlighting the uneasy coexistence of regulatory assurances and judicial skepticism.

The stakes of this legal conflict are poised to rise even higher with an impending Supreme Court decision that could reshape the terrain of product-liability law. The justices are set to consider whether federal law shields Bayer from many Roundup-related claims by virtue of the EPA’s regulatory determinations. Should the Court side with Bayer, a substantial portion of the more than 40,000 active lawsuits could be dismissed or severely curtailed. For plaintiffs’ lawyers, the urgency of securing compensation before such a ruling is palpable.

Christopher Seeger, one of the lead attorneys for the plaintiffs, underscored this imperative, warning that a Bayer victory at the Supreme Court could leave many claimants without recourse. The New York Times report framed the looming decision as a crucible not only for Bayer but also for the broader doctrine of federal preemption, with implications that could ripple across industries regulated by federal agencies.

Bayer’s leadership has characterized the settlement and the Supreme Court case as complementary strategies rather than competing gambits. In Mr. Anderson’s telling, resolving a large swath of existing claims while simultaneously seeking a favorable judicial ruling that would make future litigation easier to defeat constitutes a form of “tightest possible containment” of legal risk.

It is a strategy that reflects the company’s experience of playing what executives privately describe as legal Whac-a-Mole: settling thousands of claims even as new ones continue to surface, and bracing for trials that, when they proceed, can produce eye-popping verdicts that capture public attention and inflame corporate reputational risk. While many of these verdicts are ultimately reduced on appeal, their cumulative effect has been to keep the Roundup controversy in the headlines, perpetuating uncertainty for Bayer and anxiety for shareholders.

The proposed settlement also casts a revealing light on the evolving calculus of corporate accountability in an era of mass tort litigation. By creating a fund to address future claims, Bayer is effectively acknowledging that the Roundup controversy is not merely a relic of past practices but a continuing source of potential liability. This approach reflects a broader trend of pharmaceutical and chemical litigation, toward global settlements that seek to impose a framework of predictability on inherently unpredictable legal landscapes. Yet the history of the Roundup litigation suggests that such frameworks are fragile, vulnerable to judicial scrutiny and shifting scientific debates.

Underlying the legal maneuvering is a deeper, unresolved dispute about the science of glyphosate and the evidentiary standards by which causation is established in toxic-tort cases. Regulatory agencies in multiple countries have reached differing conclusions about the carcinogenic risks of glyphosate, creating a patchwork of assessments that complicate the task of adjudicating individual claims. The New York Times has chronicled how juries, confronted with dueling expert testimony, have often been swayed by narratives of corporate concealment and personal suffering, even as regulators insist on the absence of definitive causal proof. This divergence between regulatory science and courtroom persuasion lies at the heart of Bayer’s predicament, raising enduring questions about how societies arbitrate risk in the face of scientific uncertainty.

The company’s willingness to contemplate drastic measures—Mr. Anderson has previously suggested that Bayer would cease manufacturing Roundup altogether if it could not find a way to end the lawsuits—underscores the existential weight of the controversy. For farmers around the world who rely on Roundup to control weeds and enhance crop yields, the prospect of its withdrawal raises concerns about agricultural productivity and the availability of effective alternatives. The Roundup saga thus sits at the intersection of corporate liability, regulatory policy, and food security, complicating any effort to frame the issue as a simple contest between corporate wrongdoing and legal redress.

Whether the proposed $7.25 billion settlement will withstand judicial scrutiny remains uncertain. The Missouri judge reviewing the agreement will weigh not only its adequacy in compensating current plaintiffs but also the fairness of its provisions for future claimants, mindful of the criticisms that doomed the 2020 settlement. If approved, the deal would represent one of the largest mass-tort settlements in U.S. history, a testament to the scale of the Roundup litigation and the stakes for Bayer. If rejected, it would prolong a saga that has already spanned years and consumed vast corporate and judicial resources.

In the meantime, the Roundup controversy continues to serve as a cautionary tale about the unforeseen liabilities that can accompany corporate expansion through acquisition. Bayer’s purchase of Monsanto transformed the company’s risk profile in ways that few executives could have fully anticipated, binding its corporate future to a product whose legal and scientific controversies show little sign of abating. The proposed settlement, for all its magnitude, may prove less a final reckoning than a provisional truce in a conflict that has reshaped the contours of corporate accountability in the age of mass litigation.